Entacapone - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for entacapone and what is the scope of patent protection?
Entacapone
is the generic ingredient in two branded drugs marketed by Orion Pharma, Ajanta Pharma Ltd, Alembic, Aurobindo Pharma Ltd, Macleods Pharms Ltd, Mylan Pharms Inc, Sun Pharm, Sunshine, and Wockhardt Bio Ag, and is included in nine NDAs. Additional information is available in the individual branded drug profile pages.There are twenty drug master file entries for entacapone. Fifteen suppliers are listed for this compound.
Summary for entacapone
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 9 |
NDAs: | 9 |
Drug Master File Entries: | 20 |
Finished Product Suppliers / Packagers: | 15 |
Raw Ingredient (Bulk) Api Vendors: | 100 |
Clinical Trials: | 41 |
Patent Applications: | 7,163 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price trends for entacapone |
What excipients (inactive ingredients) are in entacapone? | entacapone excipients list |
DailyMed Link: | entacapone at DailyMed |
Recent Clinical Trials for entacapone
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Xiangya Hospital of Central South University | Early Phase 1 |
Bial - Portela C S.A. | Phase 4 |
LobSor Pharmaceuticals AB | Phase 1 |
Pharmacology for entacapone
Drug Class | Catechol-O-Methyltransferase Inhibitor |
Mechanism of Action | Catechol O-Methyltransferase Inhibitors |
Paragraph IV (Patent) Challenges for ENTACAPONE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
COMTAN | Tablets | entacapone | 200 mg | 020796 | 1 | 2007-04-11 |
US Patents and Regulatory Information for entacapone
Expired US Patents for entacapone
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Orion Pharma | COMTAN | entacapone | TABLET;ORAL | 020796-001 | Oct 19, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Orion Pharma | COMTAN | entacapone | TABLET;ORAL | 020796-001 | Oct 19, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Orion Pharma | COMTAN | entacapone | TABLET;ORAL | 020796-001 | Oct 19, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Orion Pharma | COMTAN | entacapone | TABLET;ORAL | 020796-001 | Oct 19, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
Orion Pharma | COMTAN | entacapone | TABLET;ORAL | 020796-001 | Oct 19, 1999 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for entacapone
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Orion Corporation | Entacapone Orion | entacapone | EMEA/H/C/002440 Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations. |
Authorised | no | no | no | 2011-08-18 | |
Orion Corporation | Comtess | entacapone | EMEA/H/C/000170 Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations. |
Authorised | no | no | no | 1998-09-16 | |
Orion Corporation | Comtan | entacapone | EMEA/H/C/000171 Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations. |
Authorised | no | no | no | 1998-09-22 | |
Teva Pharma B.V. | Entacapone Teva | entacapone | EMEA/H/C/002075 Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations. |
Authorised | yes | no | no | 2011-02-18 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.